Hookipa Pharma Inc (NASDAQ:HOOK) has a beta value of 0.96 and has seen 2.88 million shares traded in the last trading session. The company, currently valued at $88.39M, closed the last trade at $0.89 per share which meant it gained $0.08 on the day or 10.82% during that session. The HOOK stock price is -130.34% off its 52-week high price of $2.05 and 53.93% above the 52-week low of $0.41. The 3-month trading volume is 738.48K shares.
Hookipa Pharma Inc (NASDAQ:HOOK) trade information
Sporting 10.82% in the green in last session, the stock has traded in the green over the last five days, when the HOOK stock price touched $0.89 or saw a rise of 6.21%. Year-to-date, Hookipa Pharma Inc shares have moved 10.28%, while the 5-day performance has seen it change 21.87%. Over the past 30 days, the shares of Hookipa Pharma Inc (NASDAQ:HOOK) have changed 24.00%.
Hookipa Pharma Inc (HOOK) estimates and forecasts
Figures show that Hookipa Pharma Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 95.47% over the past 6 months, with this year growth rate of 32.00%, compared to 12.90% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are 63.00% and 77.30% for the next quarter. Revenue growth from the last financial year stood is estimated to be 63.40%.
3 analysts offering their estimates for the company have set an average revenue estimate of $2.8 million for the current quarter. 3 have an estimated revenue figure of $10.47 million for the next quarter concluding in Jun 2024. Year-ago sales stood $4.39 million and $2.68 million respectively for this quarter and the next, and analysts expect sales will shrink by -36.20% for the current quarter and 290.80% for the next.
Earnings growth for 2024 is a modest 58.43% while over the next 5 years, the company’s earnings are expected to increase by 14.50%.
HOOK Dividends
Hookipa Pharma Inc is expected to release its next earnings report in May this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
